Ashutosh Lal, MD

I am a hematologist at UCSF Benioff Children’s Hospital Oakland, Director of Clinical Hematology, and Director of the Comprehensive Thalassemia Center and Iron Disorders Program. I spend 50% time in clinic and 50% in research. My long-term academic and clinical interests are thalassemia, iron overload, and nutrition. The Thalassemia Program in Oakland is the largest clinical program in the country managing over 300 active patients. My research portfolio extends from natural history studies, molecular diagnostics, iron quantification, micronutrient deficiencies, to clinical trials in iron chelation, new disease-modifying agents, and gene therapy for beta thalassemia. My center is supported by HRSA and CDC to study the prevalence and complications of thalassemia in the U.S. and to develop evidence-based standards care for thalassemia. I am the coordinator of the Thalassemia Western Consortium, an association of twelve academic hematology programs in the western states, to improve training and management of thalassemia care. Alpha thalassemia is a special emphasis area where we have delineated the genotype-phenotype relationship in alpha thalassemia, published international guidelines for managing HbH disease, postnatal care of alpha thalassemia major. I am invested in the development of gene therapy approaches to severe forms of thalassemia. I provide consultation and care for complex iron overload in non-hematological conditions in children and adults.

  1. Tavassoli S, Chung JH, Panigrahi AR, Shahsavar A, Lal A, Singer ST. Hemoglobin Balkh, a Novel Mutation in Codon 132 of α2-Globin Gene [α132(H15) (+T) or HBA2:C.396dup (p.Val134fs)]: A Case Report and Insight into the Pathophysiology. Hemoglobin 2024. PMID: 39415483


  2. Lal A, Viprakasit V, Vichinsky E, Lai Y, Lu MY, Kattamis A. Disease burden, management strategies, and unmet needs in α-thalassemia due to hemoglobin H disease. American journal of hematology 2024. PMID: 39037279


  3. Erlich HA, Ko L, Lee J, Eaton K, Calloway CD, Lal A, Das R, Jamwal M, Lopez-Pena C, Mack SJ. Non-invasive prenatal testing of beta-hemoglobinopathies using next generation sequencing, in-silico sequence size selection, and haplotyping. Croatian medical journal 2024. PMID: 38868964


  4. Mark C. Walters, Alexis A. Thompson, Timothy S. Olson, John B. Porter, Jennifer Schneiderman, Suradej Hongeng, Andreas E. Kulozik, Marina Cavazzana, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, John E.J. Rasko, Evangelia Yannaki, Shamshad Ali, Ge Tao, Himal L. Thakar, Ami Deora, Katiana Gruppioni, Richard A. Colvin, Franco Locatelli, Janet L. Kwiatkowski. Sustained Efficacy and Safety in Adult and Pediatric Patients with Transfusion-Dependent ß-Thalassemia up to 9 Years Post Treatment with Betibeglogene Autotemcel (Beti-cel). Transplantation and cellular therapy 2024. PMID:


  5. Janet L. Kwiatkowski, Timothy S. Olson, Mark C. Walters, John B. Porter, Jennifer Schneiderman, Suradej Hongeng, Andreas Kulozik, Marina Cavazzana, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, John E. J. Rasko, Evangelia Yannaki, Shamshad Ali, Gloria Tao, Ami Deora, Himal L. Thakar, Richard A. Colvin, Franco Locatelli, Alexis A. Thompson. Improvement in Iron Burden in Patients with Transfusion-Dependent ß-Thalassemia (TDT) Treated with Betibeglogene Autotemcel (Beti-cel) Gene Therapy: Up to 9 Years of Follow-up. Blood 2023. PMID:


  6. Beth Apsel Winger, Felicity Usac, Liusheng Huang, Ashutosh Lal, Janel R. Long-Boyle. Pharmacokinetics (PK) of Deferasirox in Transfusion Dependent Thalassemia. Blood 2023. PMID:


  7. Alexis A. Thompson, Timothy S. Olson, Mark C. Walters, John B. Porter, Jennifer Schneiderman, Suradej Hongeng, Andreas Kulozik, Marina Cavazzana, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, John E. J. Rasko, Evangelia Yannaki, Shamshad Ali, Gloria Tao, Himal L. Thakar, Ami Deora, Katiana Gruppioni, Richard A. Colvin, Franco Locatelli, Janet L. Kwiatkowski. Sustained Efficacy, Safety, and Improved Quality of Life in Adult and Pediatric Patients with Transfusion-Dependent ß-Thalassemia up to 9 Years Post Treatment with Betibeglogene Autotemcel (Beti-cel). Blood 2023. PMID:


  8. Lal A, Vichinsky E. The Clinical Phenotypes of Alpha Thalassemia. Hematology/oncology clinics of North America 2023. PMID: 36907606


  9. Timothy S. Olson, Mark C. Walters, Janet L. Kwiatkowski, John B. Porter, Jennifer Schneiderman, Suradej Hongeng, Andreas E. Kulozik, Marina Cavazzana, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, John E.J. Rasko, Evangelia Yannaki, Shamshad Ali, Richard A. Colvin, Franco Locatelli, Alexis A. Thompson. 385 Long-term Outcomes of 63 Patients with Transfusion-Dependent ß-Thalassemia (TDT) Followed-up to 7 Years after Treatment with betibeglogene autotemcel (beti-cel) Gene Therapy (GT) and Factors Impacting Neutrophil and Platelet Engraftment. Transplantation and cellular therapy 2023. PMID:


  10. Mark C. Walters, Janet L. Kwiatkowski, John B. Porter, Jennifer Schneiderman, Suradej Hongeng, Andreas E. Kulozik, Marina Cavazzana, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, John E.J. Rasko, Evangelia Yannaki, Shamshad Ali, Ilya Shestopalov, Maeva Fincker, Richard A. Colvin, Dustin Whitney, Franco Locatelli, Alexis A. Thompson. Long Term Outcomes of 63 Patients with Transfusion-Dependent ß-Thalassemia (TDT) Followed up to 7 Years Post-Treatment with betibeglogene autotemcel (beti-cel) Gene Therapy and Exploratory Analysis of Predictors of Successful Treatment Outcomes in Phase Blood 2022. PMID:


  11. Kevin H.M. Kuo, D. Mark Layton, Ashutosh Lal, Hanny Al-Samkari, Penelope A. Kosinski, Bo Tong, Jeremie H. Estepp, Katrin Uhlig, Elliott P. Vichinsky. Mitapivat Improves Markers of Erythropoietic Activity in Long-Term Study of Adults with Alpha- or Beta-Non-Transfusion-Dependent Thalassemia. Blood 2022. PMID:


  12. Ayca Erkin-Cakmak, Tariq Ahmad, Anne Rishon, Marcela Weyhmiller, Ellen Fung, Maya Lodish, Ashutosh Lal. PSUN160 Transfusion Related Endocrinopathies and Thalassemia (TREAT) Study. Journal of the Endocrine Society 2022. PMID:


  13. KH Kuo, DM Layton, A Lal, H Al-Samkari, J Bhatia, PA Kosinski, B Tong, M Lynch, K Uhlig, EP Vichinsky. LONG-TERM EFFICACY AND SAFETY OF THE ORAL PYRUVATE KINASE ACTIVATOR MITAPIVAT IN ADULTS WITH NON–TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA. Hematology Transfusion and Cell Therapy 2022. PMID:


  14. Kuo KHM, Layton DM, Lal A, Al-Samkari H, Bhatia J, Kosinski PA, Tong B, Lynch M, Uhlig K, Vichinsky EP. Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent a-thalassaemia or �-thalassaemia: an open-label, multicentre, phase 2 study. Lancet (London, England) 2022. PMID: 35964609


  15. Fung EB, Goldberg EK, Bambot S, Manzo R, Lal A. Relationships among Physical Activity, Pain, and Bone Health in Youth and Adults with Thalassemia: An Observational Study. Thalassemia Reports 2022. PMID: 37139496


  16. COATES T., LAL A., BROWN R., KALFA T., KWIATKOWSKI J., BREVARD J., TRENOR C., WOOD K., SHETH S.. P-055: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE. HemaSphere 2022. PMID:


  17. V. Viprakasit, M. D. Cappellini, J. B. Porter, K. H. M. Kuo, T. D. Coates, E. Voskaridou, V. M. Pinto, I. Tartaglione, A. Khelif, A. Lal, A. Kattamis, A. Piga, O. Hermine, N. Holot, F. Lersch, J. K. Shetty, J. Zhang, L. Bueno, A. C. Giuseppi, D. Miteva, A. T. Taher. P1518: LONG-TERM SAFETY RESULTS OF THE BELIEVE STUDY OF LUSPATERCEPT IN ADULTS WITH ?ETA-THALASSEMIA. HemaSphere 2022. PMID:


  18. K. H. M. Kuo, D. M. Layton, A. Lal, H. Al-Samkari, J. Bhatia, P. A. Kosinski, B. Tong, M. Lynch, K. Uhlig, E. P. Vichinsky. P1522: LONG-TERM EFFICACY AND SAFETY OF THE ORAL PYRUVATE KINASE ACTIVATOR MITAPIVAT IN ADULTS WITH NON–TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA. HemaSphere 2022. PMID:


  19. A. Lal, R. C. Brown, T. Coates, T. Kalfa, J. Kwiatkowski, J. Brevard, C. Trenor, K. Wood, S. Sheth. PB2232: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE. HemaSphere 2022. PMID:


  20. M. D. Cappellini, A. T. Taher, J. B. Porter, K. H. Kuo, T. D. Coates, E. Voskaridou, G. L. Forni, S. Perrotta, A. Khelif, A. Lal, A. Kattamis, A. Piga, O. Hermine, N. Holot, F. Lersch, J. K. Shetty, S. Vodala, J. Zhang, D. Miteva, V. Viprakasit. S270: LONGER-TERM ANALYSIS OF EFFICACY OF LUSPATERCEPT VERSUS PLACEBO IN PATIENTS WITH TRANSFUSION-DEPENDENT BETA-THALASSEMIA ENROLLED IN THE BELIEVE STUDY. HemaSphere 2022. PMID:


  21. Erlich HA, López-Peña C, Carlberg KT, Shih S, Bali G, Yamaguchi KD, Salamon H, Das R, Lal A, Calloway CD. Non-Invasive Prenatal Test for β-Thalassemia and Sickle Cell Disease Using Probe Capture Enrichment and Next-Generation Sequencing of DNA in Maternal Plasma. 2021. PMID: 34849992


  22. Jennifer Schneiderman, Franco Locatelli, Alexis A. Thompson, Janet L. Kwiatkowski, John B. Porter, Suradej Hongeng, Andreas E. Kulozik, Marina Cavazzana, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, John E.J. Rasko, Evangelia Yannaki, Manfred Schmidt, Lin Du, Richard A. Colvin, Mark C. Walters. 28 Efficacy and Safety of Betibeglogene Autotemcel (beti-cel) Gene Therapy in 63 Patients with Transfusion-Dependent ß-Thalassemia (TDT): 7-Year Post-Infusion Follow-up of Phase 1/2 and Phase 3 Studies. Transplantation and cellular therapy 2022. PMID:


  23. A. Lal, C. Brown, T. Coates, T. Kalfa, J.L. Kwiatkowski, J. Brevard, C. Trenor, K. Wood, S. Sheth. S103: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE PKR ACTIVATOR ETAVOPIVAT (FT-4202) IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE. HemaSphere 2022. PMID:


  24. K Kuo, D Layton, A Lal, H Al-Samkari, J Bhatia, P Kosinski, B Tong, M Lynch, K Uhlig, E Vichinsky. S116: LONG-TERM EFFICACY AND SAFETY OF THE ORAL PYRUVATE KINASE ACTIVATOR MITAPIVAT IN ADULTS WITH NON—TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA. HemaSphere 2022. PMID:


  25. Goldberg EK, Lal A, Fung EB. Nutrition in Thalassemia: A Systematic Review of Deficiency, Relations to Morbidity, and Supplementation Recommendations. 2021. PMID: 34486568


  26. MacKenzie TC, Amid A, Angastiniotis M, Butler C, Gilbert S, Gonzalez J, Keller RL, Kharbanda S, Kirby-Allen MA, Koenig BA, Kyono W, Lal A, Lianoglou BR, Norton ME, Ogasawara KK, Panchalee T, Rosner M, Schwab ME, Thompson AA, Waye JS, Vichinsky E. Consensus statement for the perinatal management of patients with alpha thalassemia major. 2021. PMID: 34749399


  27. Locatelli F, Thompson AA, Kwiatkowski JL, Porter JB, Thrasher AJ, Hongeng S, Sauer MG, Thuret I, Lal A, Algeri M, Schneiderman J, Olson TS, Carpenter B, Amrolia PJ, Anurathapan U, Schambach A, Chabannon C, Schmidt M, Labik I, Elliot H, Guo R, Asmal M, Colvin RA, Walters MC. Betibeglogene Autotemcel Gene Therapy for Non-β0/β0 Genotype β-Thalassemia. 2021. PMID: 34891223


  28. Janet L. Kwiatkowski, Franco Locatelli, Mark C. Walters, John B. Porter, Suradej Hongeng, Evangelia Yannaki, Andreas E. Kulozik, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, Ruiting Guo, Richard A. Colvin, Katiana Gruppioni, Alexis A. Thompson. Improvement in Health-Related Quality of Life Following Treatment with Betibeglogene Autotemcel in Patients with Transfusion-Dependent ß-Thalassemia Enrolled in Phase 3 Studies. 2021. PMID:


  29. Kevin H.M. Kuo, D. Mark Layton, Ashutosh Lal, Hanny Al-Samkari, Joy Bhatia, Penelope A. Kosinski, Bo Tong, Megan Lynch, Katrin Uhlig, Elliott Vichinsky. Long-Term Efficacy and Safety of the Oral Pyruvate Kinase Activator Mitapivat in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia. 2021. PMID:


  30. Alexis A. Thompson, Franco Locatelli, Evangelia Yannaki, Mark C. Walters, John B. Porter, Suradej Hongeng, Andreas E. Kulozik, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, Marina Cavazzana, John E.J. Rasko, Lin Du, Richard A. Colvin, Janet L. Kwiatkowski. Restoring Iron Homeostasis in Pts Who Achieved Transfusion Independence after Treatment with Betibeglogene Autotemcel Gene Therapy: Results from up to 7 Years of Follow-up. 2021. PMID:


  31. Ashutosh Lal, R. Clark Clark Brown, Thomas D. Coates, Theodosia A. Kalfa, Janet L. Kwiatkowski, Julie Brevard, Von Potter, Ken W. Wood, Sujit Sheth. Trial in Progress: A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of the PKR Activator Etavopivat (FT-4202) in Patients with Thalassemia or Sickle Cell Disease. 2021. PMID:


  32. KH Kuo, DM Layton, A Lal, H Al-Samkari, J Bhatia, B Tong, M Lynch, K Uhlig, EP Vichinsky. RESULTS FROM A PHASE 2 STUDY OF MITAPIVAT IN ADULTS WITH NON–TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA. 2021. PMID:


  33. Lal A, Wong T, Keel S, Pagano M, Chung J, Kamdar A, Rao L, Ikeda A, Puthenveetil G, Shah S, Yu J, Vichinsky E. The transfusion management of beta thalassemia in the United States. 2021. PMID: 34453453


  34. Singer ST, Fischer R, Allen I, Lal A, Vichinsky E, Yuan Q, Wang ZJ. Pituitary iron and factors predictive of fertility status in transfusion dependent thalassemia. 2021. PMID: 33121232


  35. Suradej Hongeng, Alexis A. Thompson, Janet L. Kwiatkowski, Franco Locatelli, John B. Porter, John Rasko, Marina Cavazzana, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, Andreas E. Kulozik, Evangelia Yannaki, Manfred Schmidt, Ying Chen, Ruiting Guo, Weijian Liu, Richard A. Colvin, Mark C. Walters. 1 Efficacy and Safety of Betibeglogene Autotemcel (beti-cel; LentiGlobin for ß-thalassemia) Gene Therapy in 60 Patients with Transfusion-Dependent ß-Thalassemia (TDT) Followed for up to 6 Years Post-Infusion. 2021. PMID:


  36. Mark C. Walters, Janet L. Kwiatkowski, John B. Porter, Suradej Hongeng, Evangelia Yannaki, Andreas E. Kulozik, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, Ruiting Guo, Weijian Liu, Richard A. Colvin, Franco Locatelli, Alexis A. Thompson. 122 Safety and Efficacy Outcomes in Pediatric Patients with Transfusion-Dependent ß-Thalassemia (TDT) Receiving Betibeglogene Autotemcel (beti-cel; LentiGlobin for ß-thalassemia) Gene Therapy in the Phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3 2021. PMID:


  37. Lal A. Challenges in chronic transfusion for patients with thalassemia. 2020. PMID: 33275743


  38. Alexis A. Thompson, Janet L. Kwiatkowski, John B. Porter, Suradej Hongeng, Evangelia Yannaki, Andreas E. Kulozik, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, Ruiting Guo, Weijian Liu, Richard A. Colvin, Mark C. Walters, Franco Locatelli. Favorable Outcomes in Pediatric Patients in the Phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3) Studies of Betibeglogene Autotemcel Gene Therapy for the Treatment of Transfusion-Dependent ß-Thalassemia. 2020. PMID:


  39. Olivier Hermine, Maria Domenica Cappellini, Ali T. Taher, Thomas D. Coates, Vip Viprakasit, Ersi Voskaridou, Ashutosh Lal, Hong Keng Liew, Silverio Perrotta, Abderrahim Khelif, Antonis Kattamis, Jeevan K. Shetty, George Zhang, Yu (Olivia) Tian, Dimana Miteva, Tatiana Zinger, Derek Tang, Jay T. Backstrom, John B. Porter. Longitudinal Effect of Luspatercept Treatment on Iron Overload and Iron Chelation Therapy (ICT) in Adult Patients (Pts) with ß-Thalassemia in the Believe Trial. Blood 2020. PMID:


  40. Mark C. Walters, David H.K. Chui, John J Farrell, Ashutosh Lal, Franco Locatelli, Janet L. Kwiatkowski, John B. Porter, Martin G. Sauer, Isabelle Thuret, Suradej Hongeng, Andreas E. Kulozik, Adrian J. Thrasher, Evangelia Yannaki, Julia Yang, Dustin Whitney, Alexandria Petrusich, Richard A. Colvin, Alexis A. Thompson. Response of Patients with Transfusion-Dependent ß-Thalassemia (TDT) to Betibeglogene Autotemcel (beti-cel; LentiGlobin for ß-Thalassemia) Gene Therapy Based on HBB Genotype and Disease Genetic Modifiers. Blood 2020. PMID:


  41. Fung EB, Ahmad T, Killilea DW, Hussain R, Lal A. Zinc supplementation improves markers of glucose homeostasis in thalassaemia. British journal of haematology 2020. PMID: 32488893


  42. Cappellini MD, Viprakasit V, Taher AT, Georgiev P, Kuo KHM, Coates T, Voskaridou E, Liew HK, Pazgal-Kobrowski I, Forni GL, Perrotta S, Khelif A, Lal A, Kattamis A, Vlachaki E, Origa R, Aydinok Y, Bejaoui M, Ho PJ, Chew LP, Bee PC, Lim SM, Lu MY, Tantiworawit A, Ganeva P, Gercheva L, Shah F, Neufeld EJ, Thompson A, Laadem A, Shetty JK, Zou J, Zhang J, Miteva D, Zinger T, Linde PG, Sherman ML, Hermine O, Porter J, Piga A, BELIEVE Investigators. A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia. 2020. PMID: 32212518


  43. Jennifer Schneiderman, Alexis A. Thompson, Mark C. Walters, Janet L. Kwiatkowski, Andreas E. Kulozik, Martin G. Sauer, John B. Porter, Isabelle Thuret, Suradej Hongeng, Ashutosh Lal, Adrian J. Thrasher, Evangelia Yannaki, Heidi Elliot, Ge Tao, Weijian Liu, Richard A. Colvin, Franco Locatelli. Interim Results from the Phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3) Studies of Betibeglogene Autotemcel Gene Therapy (LentiGlobin) for the Treatment of Transfusion-Dependent ß-Thalassemia. 2020. PMID:


  44. Bansal D, Lal A. Taking Stock of Hemophilia, Immune Thrombocytopenia, and Bone Marrow Failure. 2020. PMID: 31900847


  45. Bansal D, Lal A. Iron Metabolism, Hemolytic Anemia, and Thalassemia. 2019. PMID: 31828597


  46. Ashutosh Lal, Franco Locatelli, Janet L. Kwiatkowski, Andreas E. Kulozik, Evangelia Yannaki, John B. Porter, Isabelle Thuret, Martin G. Sauer, Heidi Elliot, Ying Chen, Richard A. Colvin, Alexis A. Thompson. Northstar-3: Interim Results from a Phase 3 Study Evaluating Lentiglobin Gene Therapy in Patients with Transfusion-Dependent ß-Thalassemia and Either a ß0 or IVS-I-110 Mutation at Both Alleles of the HBB Gene. 2019. PMID:


  47. Ashutosh Lal, Roland Fischer, Elliott Vichinsky, Marcela Weyhmiller. Trends in Iron Overload over Past Two Decades: Results from the Natural History of Iron Burden Study with the SQUID Biosusceptometer. 2019. PMID:


  48. Lal A, Bansal D. Thalassemia: Common Clinical Queries in Management. 2019. PMID: 31620986


  49. R. McKinnon, J. McCann, B. Ames, M. Shigenaga, A. Lal, J. Suh, R. Krauss, G. Gildengorin, A. Goldrich, S. Shenvi. Multicomponent Nutrient Bar Promotes Weight Loss and Improves Dyslipidemia and Insulin Resistance. 2019. PMID:


  50. Lal A. Iron in Health and Disease: An Update. 2019. PMID: 31520313


  51. A. E. Kulozik, F. Locatelli, E. Yannaki, J. B. Porter, I. Thuret, M. G. Sauer, A. Lal, J. L. Kwiatkowski, H. Elliot, G. Tao, R. A. Colvin, A. A. Thompson. RESULTS FROM THE PHASE 3 NORTHSTAR-3 STUDY EVALUATING LENTIGLOBIN GENE THERAPY IN PATIENTS WITH TRANSFUSION-DEPENDENT ß-THALASSAEMIA AND A ß0 OR IVS-I-110 MUTATION AT BOTH ALLELES OF THE HBB GENE. 2019. PMID:


  52. Ashutosh Lal, William Avrin, Viktoriia Kolotovska, Lisa Calvelli, Marcela Weyhmiller. Advances in Biomagnetic Liver Susceptometry Allow the Measurement of Liver Iron Concentration with a Room Temperature Sensor. 2018. PMID:


  53. Franco Locatelli, Mark C. Walters, Janet L. Kwiatkowski, John Porter, Martin G. Sauer, Isabelle Thuret, Suradej Hongeng, Andreas E. Kulozik, Ashutosh Lal, Adrian J. Thrasher, Evangelia Yannaki, Heidi Elliot, Ge Tao, Mohammed Asmal, Alexis A. Thompson. Lentiglobin Gene Therapy for Patients with Transfusion-Dependent ß-Thalassemia (TDT): Results from the Phase 3 Northstar-2 and Northstar-3 Studies. 2018. PMID:


  54. Ashutosh Lal, Sujit Sheth, Sandra Gilbert, Janet L. Kwiatkowski. Thalassemia Management Checklists: Quick Reference Guides to Reduce Disparities in the Care of Patients with Transfusion-Dependent Thalassemia. 2018. PMID:


  55. Goldberg EK, Neogi S, Lal A, Higa A, Fung E. Nutritional Deficiencies Are Common in Patients with Transfusion-Dependent Thalassemia and Associated with Iron Overload. 2018. PMID: 30569002


  56. Lal A, Wong TE, Andrews J, Balasa VV, Chung JH, Forester CM, Ikeda AK, Keel SB, Pagano MB, Puthenveetil G, Shah SJ, Yu JC, Vichinsky EP. Transfusion practices and complications in thalassemia. 2018. PMID: 30260477


  57. Bseikri M, McCann JC, Lal A, Fong E, Graves K, Goldrich A, Block D, Gildengoren GL, Mietus-Snyder M, Shigenaga M, Suh J, Hardy K, Ames BN. A novel nutritional intervention improves lung function in overweight/obese adolescents with poorly controlled asthma: the Supplemental Nutrition in Asthma Control (SNAC) pilot study. 2018. PMID: 30024788


  58. Vichinsky E, Cohen A, Thompson AA, Giardina PJ, Lal A, Paley C, Cheng WY, McCormick N, Sasane M, Qiu Y, Kwiatkowski JL. Epidemiologic and clinical characteristics of nontransfusion-dependent thalassemia in the United States. 2018. PMID: 29637688


  59. Kreger EM, Singer ST, Witt RG, Sweeters N, Lianoglou B, Lal A, Mackenzie TC, Vichinsky E. Favorable outcomes after in utero transfusion in fetuses with alpha thalassemia major: a case series and review of the literature. 2016. PMID: 27862048


  60. Melissa Cervantes, Ashutosh Lal, Anne M Marsh, Ellen B. Fung. Assessing Bone Quality Using Trabecular Bone Score in Patients with Hemoglobinopathies. 2016. PMID:


  61. Patrick B Walter, Michael Minkley, Caitlin Curtis, Hodge Maeve, Razavi Morty, Sarah Ewing, Ashutosh Lal, Anne Higa, David Killilea, Terry Pearson, Ellen B. Fung. Implications of Low Zinc and Copper Levels As Well As Altered Iron Trafficking Proteins on Oxidant Stress in Patients with Transfusion Dependant Thalassemia. 2016. PMID:


  62. Ashutosh Lal, Marcela G Weyhmiller, Elliott Vichinsky. Threshold Ferritin Values to Predict Control of Liver Iron Burden in Thalassemia. 2016. PMID:


  63. Katie Carlberg, Nikhil Bose, Jingyi Deng, Ashutosh Lal, Henry Erlich, Cassandra Calloway. Towards the Development of a Noninvasive Prenatal Test for Beta-Thalassemia: Utilization of Probe Capture Enrichment and Next Generation Sequencing. 2016. PMID:


  64. Patrick B Walter, Michael Minkley, Caitlin Curtis, Maeve Hodge, Razavi Morty, Sarah Ewing, Zoe Ennis, Ashutosh Lal, Annie Higa, David Killilea, Terry Pearson, Ellen Fung. 469 Implications of Altered Trace Minerals and Iron Trafficking Proteins on Oxidant Stress in Thalassemia. 2016. PMID:


  65. Lal A, Gomez E, Calloway C. Increased mitochondrial DNA deletions and copy number in transfusion-dependent thalassemia. 2016. PMID: 27583305


  66. Lal A. Assessment and treatment of pain in thalassemia. 2016. PMID: 27124110


  67. E.B. Fung, C. Schroepfer, A. Lal. 19. Nutrition for patients with thalassemia. 2016. PMID:


  68. Patrick B. Walter, Nick Slater, Paul Harmatz, Annie Higa, Vivian Ng, Marcels Weyhmiller, Patricia Evans, John B Porter, Nancy Sweeters, Jackson Price, David Killilea, Lynne Neumayr, Ashutosh Lal, Elliott Vichinsky. Iron Level and Monocyte Morphology Predict TLR4 Expression and Reactive Oxygen Species Production Which Influences Chronic Inflammation in ß-Thalassemia. 2015. PMID:


  69. Ellen Fung, Nan Luo, Ginny Gildengorin, Ashutosh Lal. The effect of iron chelators on bone health in patients with thalassemia. 2015. PMID:


  70. Fung EB, Gildengorin G, Talwar S, Hagar L, Lal A. Zinc status affects glucose homeostasis and insulin secretion in patients with thalassemia. 2015. PMID: 26043030


  71. McCann JC, Shigenaga MK, Mietus-Snyder ML, Lal A, Suh JH, Krauss RM, Gildengorin GL, Goldrich AM, Block DS, Shenvi SV, McHugh TH, Olson DA, Ames BN. A multicomponent nutrient bar promotes weight loss and improves dyslipidemia and insulin resistance in the overweight/obese: chronic inflammation blunts these improvements. 2015. PMID: 25900806


  72. Lal A, Patterson L, Goldrich A, Marsh A. Point-of-care end-tidal carbon monoxide reflects severity of hemolysis in sickle cell anemia. 2015. PMID: 25683629


  73. Ellen B. Fung, Neogi Sushrita, Drucilla Haines, Connie Schroepfer, Ashutosh Lal. Dietary Intake Insufficient to Support Nutritional Adequacy in Patients with Thalassemia. 2014. PMID:


  74. Ashutosh Lal, Kristen Yen, Lasandra Patterson, Alisa Goldrich, Anne M Marsh, Anish Bhatnagar. Elevated End-Tidal Carbon Monoxide Concentration in Children with Sickle Cell Anemia. 2014. PMID:


  75. Nicholas Richard Slater, Paul Harmatz, Annie Higa, Vivian Ng, Marcela G G Weyhmiller, Patricia Evans, John B Porter, Nancy Sweeters, Jackson Price, Alisha Manji, Angela Manocha, David W Killilea, Ashutosh Lal, Lynne Neumayr, Elliot Vichinsky, Patrick B Walter. 138 Iron Overload and Hemolysis Modulate Monocytes and Inflammation in ß-Thalassemia. 2014. PMID:


  76. Patrick B Walter, Annie Higa, Vivian Ng, Marcela G Weyhmiller, Nick R Slater, Patricia Evans, John B Porter, Nancy Sweeters, Jackson Price, Alisha Manji, David Killilea, Ashutosh Lal, Elliott Vichinsky. Association Of Cardiac Iron By T2* With Innate Immune Markers In Transfusion-Dependent Thalassemia Patients Undergoing Combined Chelation Therapy. 2013. PMID:


  77. Haven M. Allard, Marcela G. Weyhmiller, Ashutosh Lal, Ellen B. Fung. In-Accuracy Of Bone Density Measurements By DXA In Patients With Hemoglobinopathies and Iron Overload. 2013. PMID:


  78. Esteban Gomez, Cassandra Calloway, Sang Hoon Lee, Jay Kim, Navpreet Dhillon, Ginny Gildengorin, Ashutosh Lal. Mitochondrial Genome Changes As a Measure Of Iron-Induced Mitochondrial Stress In Transfusion-Dependent Thalassemia. 2013. PMID:


  79. Patrick B Walter, Paul Harmatz, Annie Higa, Vivian Ng, Marcela G Weyhmiller, Patricia Evans, John B. Porter, Nancy Sweeters, Jackson Price, Alisha Manji, David Killilea, Ashutosh Lal, Elliott Vichinsky. Innate Immune Cell Expression of Pattern Recognition Receptors From ß-Thalassemia Patients During Intensive Combination Chelation Therapy. 2012. PMID:


  80. Lal A, Porter J, Sweeters N, Ng V, Evans P, Neumayr L, Kurio G, Harmatz P, Vichinsky E. Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood cells, molecules & diseases 2012. PMID: 23151373


  81. Mietus-Snyder ML, Shigenaga MK, Suh JH, Shenvi SV, Lal A, McHugh T, Olson D, Lilienstein J, Krauss RM, Gildengoren G, McCann JC, Ames BN. A nutrient-dense, high-fiber, fruit-based supplement bar increases HDL cholesterol, particularly large HDL, lowers homocysteine, and raises glutathione in a 2-wk trial. 2012. PMID: 22549511


  82. Michele Mietus-Snyder, Mark K Shigenaga, Jung H Suh, Swapna V Shenvi, Ashutosh Lal, Tara McHugh, Donald Olson, Joyce C McCann, Ronald M Krauss, Bruce N Ames. Abstract P217: Metabolic Effects of a Nutrient-Dense High Fiber Supplement. 2012. PMID:


  83. Ellen B Fung, Kathryn N Reget, Drucilla Haines, Aenor Sawyer, Ashutosh Lal. Exploring Vertebral Height Deficits in Patients with Thalassemia and Sickle Cell Disease,. 2011. PMID:


  84. Sylvia T Singer, Elliott Vichinsky, Marcelle Cedars, Ginny Gildengorin, Jung H Suh, Ashutosh Lal. Oxidative Stress and Reproductive Capacity in Iron Overload Thalassemia Major Women. 2011. PMID:


  85. Fung EB, Aguilar C, Micaily I, Haines D, Lal A. Treatment of vitamin D deficiency in transfusion-dependent thalassemia. 2011. PMID: 21818763


  86. Lal A, Goldrich ML, Haines DA, Azimi M, Singer ST, Vichinsky EP. Heterogeneity of hemoglobin H disease in childhood. 2011. PMID: 21345100


  87. Lal A, Ames BN. Association of chromosome damage detected as micronuclei with hematological diseases and micronutrient status. 2011. PMID: 21164183


  88. Ashutosh Lal, Ida Micaily, Drucilla Foote, Ellen Fung. A Simple Regimen to Correct Vitamin D Deficiency In Transfusion-Dependent Thalassemia with High-Dose Ergocalciferol. 2010. PMID:


  89. Ashutosh Lal, Nancy Sweeters, Vivian Ng, Drucilla Foote, Patricia Evans, Lynne Neumayr, Gregory Kurio, Paul Harmatz, John B. Porter, Elliott Vichinsky. Combined Chelation Therapy with Deferasirox and Deferoxamine In Transfusion-Dependent Thalassemia. 2010. PMID:


  90. Ashutosh Lal, Michael Lee Goldrich, Drucilla Foote, Mahin Azimi, Sylvia Titi Singer, Elliott Vichinsky. Longitudinal Follow-up From Newborn Screening Reveals Deletional Hemoglobin H Disease and Hemoglobin H Constant Spring Disease Are Distinct Thalassemia Syndromes. 2010. PMID:


  91. Catherine Garie´py, Ashutosh Lal, Ellen Fung. Reduced Physical Activity In Adult and Pediatric Patients with Thalassemia. 2010. PMID:


  92. Ashutosh Lal, Elliott P Vichinsky. Sickle Cell Disease. 2010. PMID:


  93. Anurag K. Agrawal, Jung H. Suh, Bruce N. Ames, Elliott P. Vichinsky, Ashutosh Lal. Heightened Sulfur Amino Acid Oxidation in Plasma and Erythrocytes in ß-Thalassemia Major. 2009. PMID:


  94. Ashutosh Lal, Nancy Sweeters, Matt Herz, Dru Foote, Lynne Neumayr, Greg Kurio, Paul R Harmatz, Elliott P Vichinsky. Safety of Combined Chelation Therapy with Deferasirox and Deferoxamine in Transfusion-Dependent Thalassemia. 2009. PMID:


  95. Suh JH, Kim R, Yavuz B, Lee D, Lal A, Ames BN, Shigenaga MK. Clinical assay of four thiol amino acid redox couples by LC-MS/MS: utility in thalassemia. 2009. PMID: 19616487


  96. Ellen Fung, Yan Xu, Janet Kwiatkowski, Sylvia Titi Singer, Ashutosh Lal, Maria G Vogiatzi, Nancy F. Olivieri, Ellis J. Neufeld, Elliott Vichinsky, Patricia Giardina. Body Composition and Its Relationship to Growth and Bone Mass in Patients with Thalassemia. 2008. PMID:


  97. Titi Singer, Hae-Young Kim, Nancy F Olivieri, Janet Kwiatkowski, Ashutosh Lal, Thomas D. Coates, Susan Carson, Melody J. Cunningham, Patricia J Giardina, Brigitta U Mueller, Charles Quinn, Elliott Vichinsky, Thalassemia Clinical Research Network. Hemoglobin H-Constant Spring in North America: A Common Alpha Thalassemia with Frequent Complications. 2008. PMID:


  98. Lal A, Atamna W, Killilea DW, Suh JH, Ames BN. Lipoic acid and acetyl-carnitine reverse iron-induced oxidative stress in human fibroblasts. 2008. PMID: 18284845


  99. Ashutosh Lal, Jung Suh, Wafa Atamna, Bridget Canty, Ward Hagar, Elliott Vichinsky, Frans Kuypers, Bruce Ames. Anti-Oxidant Treatment with a-Lipoic Acid and Acetyl L-Carnitine in Hemoglobinopathies. 2007. PMID:


  100. Lal A, Fung EB, Pakbaz Z, Hackney-Stephens E, Vichinsky EP. Bone mineral density in children with sickle cell anemia. 2006. PMID: 16317761


  101. A. Lal, E.B. Fung, Z. Pakbaz, E.P. Vichinsky. Bone mineral density in children and young adults with beta-thalassemia major conventionally treated—RESPONSE. 2006. PMID:


  102. Ashutosh Lal, Jung H. Suh, Bruce N. Ames. Efficacy of Alpha-Lipoic Acid in Iron-Induced Oxidative Stress. 2005. PMID:


  103. Ashutosh Lal, Amrita Bhagat, Wafa Atamna, Tal Offer, Elliott P. Vichinsky, Frans A. Kuypers, Bruce N. Ames. Increased Chromosomal Breaks in Sickle Cell Disease as Evidenced by the Presence of Micronuclei in Erythrocytes. 2005. PMID:


  104. Schmidt ML, Lal A, Seeger RC, Maris JM, Shimada H, O'Leary M, Gerbing RB, Matthay KK. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005. PMID: 16116154


  105. Ashutosh Lal, Elliott P Vichinsky. Sickle Cell Disease. 2005. PMID:


  106. Offer T, Bhagat A, Lal A, Atamna W, Singer ST, Vichinsky EP, Kuypers FA, Ames BN. Measuring chromosome breaks in patients with thalassemia. 2005. PMID: 16339694


  107. Ashutosh Lal, Ellen Fung, Bamidele Kammen, Zahra Pakbaz, Nancy Sweeters, Ekua Hackney-Stevens, Keith Quirolo, Elliott Vichinsky. Evaluation of Bone Mineral Density in Children with Sickle Cell Anemia. 2004. PMID:


  108. Lal A, Vichinsky E. The role of fetal hemoglobin-enhancing agents in thalassemia. 2004. PMID: 15534853